{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:12:51Z","timestamp":1790874771694,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.jhep.2005.01.020","type":"journal-article","created":{"date-parts":[[2005,4,11]],"date-time":"2005-04-11T20:05:33Z","timestamp":1113249933000},"page":"793-798","source":"Crossref","is-referenced-by-count":124,"title":["Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C"],"prefix":"10.1016","volume":"42","author":[{"given":"Martin","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schwaiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea S.","family":"Garkisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Pich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hinzpeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Uebelhack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"van Boemmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2005.01.020_bib1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1176\/appi.ajp.157.6.867","article-title":"Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review","volume":"157","author":"Dieperink","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jhep.2005.01.020_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0278-5846(01)00324-4","article-title":"Interferon alpha (IFNalpha) and psychiatric syndromes: a review","volume":"26","author":"Schaefer","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jhep.2005.01.020_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2005.01.020_bib4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/archinte.1987.00370090055011","article-title":"Psychiatric complications of long-term interferon alfa therapy","volume":"147","author":"Renault","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jhep.2005.01.020_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-2008-1040523","article-title":"Side effects of alpha interferon","volume":"9","author":"Renault","year":"1989","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2005.01.020_bib6","first-page":"39","article-title":"Mood and cognitive side effects of interferon-alpha therapy","volume":"25","author":"Valentine","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jhep.2005.01.020_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00004714-200202000-00014","article-title":"Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system","volume":"22","author":"Bonaccorso","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jhep.2005.01.020_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/sj.mp.4000995","article-title":"Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy","volume":"7","author":"Capuron","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jhep.2005.01.020_bib9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/sj.mp.4000872","article-title":"Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation","volume":"6","author":"Maes","year":"2001","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jhep.2005.01.020_bib10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.0001-690X.2003.00230.x","article-title":"Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C","volume":"109","author":"Maes","year":"2004","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jhep.2005.01.020_bib11","first-page":"11","article-title":"The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression","volume":"29","author":"Wichers","year":"2004","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.jhep.2005.01.020_bib12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0006-3223(03)00173-2","article-title":"Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment","volume":"54","author":"Capuron","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jhep.2005.01.020_bib13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4088\/JCP.v63n0213c","article-title":"Interferon-induced depression treated with citalopram","volume":"63","author":"Farah","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jhep.2005.01.020_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4088\/JCP.v63n0304","article-title":"An open-label trial of citalopram for major depression in patients with hepatitis C","volume":"63","author":"Gleason","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jhep.2005.01.020_bib15","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.mp.4001119","article-title":"A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C","volume":"7","author":"Hauser","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jhep.2005.01.020_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJM200108023450514","article-title":"Paroxetine for the prevention of depression induced by interferon alfa","volume":"345","author":"Kraus","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.01.020_bib17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1046\/j.1365-2036.2002.01265.x","article-title":"Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C","volume":"16","author":"Kraus","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2005.01.020_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000054852","article-title":"Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis","volume":"42","author":"Schaefer","year":"2000","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jhep.2005.01.020_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.5694\/j.1326-5377.2000.tb125687.x","article-title":"Sertraline treatment of interferon-alfa-induced depressive disorder","volume":"173","author":"Schramm","year":"2000","journal-title":"Med J Aust"},{"key":"10.1016\/j.jhep.2005.01.020_bib20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0033-3182(95)71658-9","article-title":"Successful treatment of interferon-alpha-induced mood disorder with nortriptyline","volume":"36","author":"Valentine","year":"1995","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jhep.2005.01.020_bib21","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/jhep.2000.7880","article-title":"interferon alfa, and depression","volume":"31","author":"Zdilar","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.01.020_bib22","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.01.020_bib23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2005.01.020_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(98)04793-X","article-title":"Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders","volume":"354","author":"Pariante","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.01.020_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJM200207113470221","article-title":"Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis","volume":"347","author":"Pariante","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.01.020_bib26","first-page":"165","article-title":"Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness","volume":"7","author":"Van Thiel","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2005.01.020_bib27","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/S0002-9270(03)00708-1","article-title":"Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse","volume":"98","author":"Van Thiel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2005.01.020_bib28","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1176\/appi.ajp.160.7.1342","article-title":"Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy","volume":"160","author":"Capuron","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jhep.2005.01.020_bib29","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2005.01.020_bib30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2005.01.020_bib31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.1083968","article-title":"Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene","volume":"301","author":"Caspi","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jhep.2005.01.020_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1176\/appi.psy.45.1.49","article-title":"Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during Interferon alpha treatment for chronic hepatitis C","volume":"45","author":"Gochee","year":"2004","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jhep.2005.01.020_bib33","first-page":"54","article-title":"Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha","volume":"25","author":"Jones","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jhep.2005.01.020_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1023\/A:1020929415443","article-title":"Effects of chronic administration of interferon alpha A\/D on serotonergic receptors in rat brain","volume":"24","author":"Abe","year":"1999","journal-title":"Neurochem Res"},{"key":"10.1016\/j.jhep.2005.01.020_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0014-2999(98)00187-3","article-title":"Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter","volume":"349","author":"Morikawa","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jhep.2005.01.020_bib36","first-page":"255","article-title":"Neurotransmitter changes by Interferon-alpha and therapeutic implications","volume":"36","author":"Schaefer","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jhep.2005.01.020_bib37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0893-133X(01)00407-9","article-title":"Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions","volume":"26","author":"Capuron","year":"2002","journal-title":"Neuropsychopharmacology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827805001807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827805001807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T19:11:56Z","timestamp":1586200316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827805001807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0168827805001807"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2005.01.020","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}